Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon Health & Science University
3303 SW Bond Ave., CH12C
Portland, OR 97239
Phone: 503-494-3657
itom@ohsu.edu
Postdoctoral Fellowship Clinical Pharmacokinetics, University of Southern California School of Pharmacy, Los Angeles, 1987–1988
ASHP Accredited Residency in Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, 1986–1987
University of Southern California School of Pharmacy, Los Angeles, Pharm.D., 1982–1986
Los Angeles State University, Los Angeles, 1980–1982
Pasadena City College, Pasadena, 1978–1980
Matthew K. Ito's research interests are the area of lipids and vascular biology. His focus is primarily on the effects of lipid-modifying agents on endothelial dysfunction and the pharmacokinetics and pharmacodynamics behavior of these drugs. His current work is focusing on the relationship between cholesterol absorption and synthesis in predicting drug response.
Ito MK, O'Conner DT. Dermal Pretreatment and the Use of Transdermal Clonidine. American Journal of Medicine. 1991;91(suppl 1A):42S-49S.
Scranton S, Ito MK. The Effects of Bile Acid Sequestrants on Plasminogen Activator Inhibitor Type 1. Pharmacotherapy. 1997;17:202.
Ito MK, Shabetai R. Pravastatin Alone and in Combination with Low Dose Cholestyramine in Patients with Primary Hypercholesterolemia and Coronary Artery Disease. American Journal of Cardiology. 1997;80:799-802.
Ito MK. The effects of extensive and poor gastrointestinal metabolisim on the pharmacodynamics of pravastatin. Journal of Clinical Pharmacology. 1998;38:331-336.
Lin JC, Ito MK, Stolley SN et al. The Effects of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin. Journal of Clinical Pharmacology. 1999;39:86-90.
Lin JC, Ito MK. Chronic Creatine Kinase Elevation Not Associated with HMG-CoA Reductase Inhibitor Treatment. Annals of Pharmacotherapy. 1999;33:163-167.
Ito MK, Stolley SN, Morreale AP et al. Rational, Study Design, and Baseline Results of the Pravastatin to Simvastatin Conversion-Lipid Optimization Program (PSCOP). American Journal of Health-System Pharmacy. 1999;56:1107-1113.
Lin JC, Ito MK. A Drug Interaction Between Troglitazone and Simvastatin. Diabetes Care. 1999;22(12):2104-2105.
Ito MK, Delucca GM, Aldridge MA. The Relationship Between Low-Density Lipoprotein Cholesterol Goal Attainment and Prevention of Coronary Heart Disease Related Events. Journal of Cardiovascular Pharmacology and Therapeutics. 2001;6(2):129-135.
Aldridge MA, Ito MK. Colesevelam Hydrochloride: A Noval Bile Acid Binding Resin. Annals of Pharmacotherapy. 2001;35:898-907.
Ito MK. The Effects of Converting from Simvastatin to Atorvastatin on Plasminogen Activator Inhibitor Type-1. Journal of Clinical Pharmacology. 2001;41:779-782.
Ito MK, Lin JC, Morreale AP, Marcus DB, Shabetai R, Dresselhaus TR, Henry RR. Effect of Pravastatin-to-Simvastatin Conversion on Reducing Low-density Lipoprotein Cholesterol. American Journal of Health-System Pharmacy. 2001;58:1734-9.
Gupta EK, Ito MK. Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidemia. Heart Disease. 2002;4:124-137.
Lucas BD, Sanoski CA, Ito MK et al. Multicenter Treat-to-Target Cost-Effectiveness Evaluation of HMG-CoA Reductase Inhibitor Monotherapy. Journal of Applied Research. 2002;2(2):97-113.
Gupta EK, Ito MK. Ezetimibe: The First in a Novel Class of Selective Cholesterol Absorption Inhibitors. Heart Disease. 2002;4(6):399-409.
Ito MK. Advances in the understanding and management of dyslipidemia: Using niacin-based therapies. American Journal of Health-System Pharmacy. 2003;60 (Suppl 2):15-21.
Talbert RL, Pieper JA, Ito MK. Niacin and the National Cholesterol Education Program Adult Treatmet Panel III guidelines: Case studies. American Journal of Health-System Pharmacy. 2003;60 (Suppl 2):22-24.
Ito MK. The Role of the Pharmacist in Establishing Lipid Intervention Programs. Pharmacotherapy. 2003;23:41S-47S.
Ito MK. The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin. Annals of Pharmacotherapy. 2003;38(2):277-85.
Ito MK, Aldridge VE, Howard JJ, Gupta EK, Johns ST, Wong JK. Encapsulation of Pravastatin Tablets Produces Greater Low-Density Lipoprotein Cholesterol Lowering in Patients with Human Immunodeficiency Virus Infection Dyslipidemia Taking Protease Inhibitors. Journal of The American College of Cardiology. 2004;43(5 Suppl A)
Cheung RC, Gupta EK, Ito MK. Acute Coffee Ingestion Does Not Affect LDL Cholesterol Level. Annals of Pharmacotherapy. 2005;39:1209-13.
